Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension
Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension
复制标题
DOI：
10.1080/08037050902843726
复制
发表时间：
2009-01-01
期刊：
影响因子：
1.8
通讯作者：
Solar, Miroslav
中科院分区：
文献类型：
--
作者：
Ceral, Jiri;Solar, Miroslav
五类降压药已被证实对预防心血管疾病发病率和死亡率有效。在剩余的抗高血压药物中，α -1受体阻滞剂的作用得到了大多数临床证据的支持；然而，在联合治疗中，已发表的数据最多关注它们作为三线药物的使用。来自耐药高血压患者的数据仍然有限。我们研究的目的是评估多沙唑嗪在这种临床环境中的有效性和安全性。回顾性分析97例多沙唑嗪治疗顽固性高血压患者的资料。Doxazosin通常作为对其他抗高血压药物无反应或不耐受的个体的第五种抗高血压药物。多沙唑嗪的剂量为2至16毫克/天。平均随访2117个月。与doxazosin治疗相关的不良事件很少，只有5例患者（5.2%）导致停药。对34例患者进行疗效分析。在该亚组中，doxazosin治疗导致血压从15920/9214降至12616/7310 mmHg。我们发现doxazosin对于需要多种抗高血压药物联合治疗的顽固性高血压患者是一种耐受性良好且有效的药物。
Five classes of antihypertensive drugs have proven efficacy in the prevention of cardiovascular morbidity and mortality. Among the remaining antihypertensives, the action of alpha-1-blockers is supported by most clinical evidence; however, in combination therapy, the published data concern their use as third-line drugs at the most. The data from patients with drug-resistant hypertension remain limited. The aim of our study was to evaluate the efficacy and safety of doxazosin in this clinical setting. Data from 97 patients with resistant hypertension treated by doxazosin were analysed retrospectively. Doxazosin was usually added as the fifth antihypertensive drug in individuals who were either unresponsive to or intolerant of the combination of other antihypertensives. The dose of doxazosin ranged from 2 to 16 mg/day. The mean duration of follow-up was 2117 months. Adverse events related to doxazosin treatment were rare and led to discontinuation of the therapy in only five patients (5.2%). Data from 34 patients were subjected to analysis of efficacy. In this subgroup, doxazosin therapy led to the reduction of blood pressure from 15920/9214 to 12616/7310 mmHg. We found that doxazosin is a well-tolerated and effective drug for patients with resistant arterial hypertension who require a combination of multiple antihypertensive drugs.